Pharmacokinetics of Midazolam in Neonates Undergoing Extracorporeal Membrane Oxygenation
暂无分享,去创建一个
Graham Lawson | P. McCormack | H. Mulla | G. Lawson | R. Firmin | David R Upton | Richard K. Firmin | Hussain Mulla | Peter McCormack | David Robert Upton | P. Mccormack
[1] H. Mulla,et al. Effects of neonatal extracorporeal membrane oxygenation circuits on drug disposition , 2000 .
[2] H. Mulla,et al. Plasma Concentrations of Midazolam in Neonates Receiving Extracorporeal Membrane Oxygenation , 2003, ASAIO journal.
[3] S. Wrighton,et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.
[4] R. Nelson,et al. Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation , 1993 .
[5] B. Roth,et al. Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit , 1991, European Journal of Pediatrics.
[6] J. Arnold,et al. Changes in the pharmacodynamic response to fentanyl in neonates during continuous infusion. , 1991, The Journal of pediatrics.
[7] D. Rosen,et al. Fentanyl uptake by the scimed membrane oxygenator. , 1988, Journal of cardiothoracic anesthesia.
[8] A. Lloyd-Thomas,et al. Infusion of midazolam in paediatric patients after cardiac surgery. , 1986, British journal of anaesthesia.
[9] T. Cresteil,et al. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. , 1997, European journal of biochemistry.
[10] G. Tucker,et al. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. , 1999, British journal of clinical pharmacology.
[11] J. Magny,et al. Population pharmacokinetics of midazolam in neonates , 1994, Clinical pharmacology and therapeutics.
[12] P. Steer,et al. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. , 1999, Anesthesiology.
[13] Lewis B. Sheiner,et al. Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[14] D. Rosen,et al. In vitro variability in fentanyl absorption by different membrane oxygenators. , 1990, Journal of cardiothoracic anesthesia.
[15] A. Gill,et al. Steady-State Plasma Concentrations of Midazolam in Critically Ill Infants and Children , 1996, The Annals of pharmacotherapy.
[16] Lewis B. Sheiner,et al. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[17] I. Patel,et al. Increased volume of distribution prolongs midazolam half-life. , 1990, British journal of clinical pharmacology.
[18] E. Orav,et al. Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation. , 1990, Anesthesiology.
[19] F. Mattheyse,et al. The pharmacokinetics of midazolam in paediatric patients , 2004, European Journal of Clinical Pharmacology.
[20] Meindert Danhof,et al. Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers , 1992, Clinical pharmacology and therapeutics.
[21] J. Beijnen,et al. Population Pharmacokinetics of Ifosfamide and its Dechloroethylated and Hydroxylated Metabolites in Children with Malignant Disease , 2001, Clinical pharmacokinetics.
[22] H. Mulla,et al. Drug disposition during Extra Corporeal Membrane Oxygenation ECMO , 2001 .
[23] G. Koren,et al. Sequestration of fentanyl by the cardiopulmonary bypass (CPBP) , 2004, European Journal of Clinical Pharmacology.
[24] É. Jacqz-Aigrain,et al. Pharmacokinetics of midazolam in critically ill neonates , 2004, European Journal of Clinical Pharmacology.
[25] J G Reves,et al. Midazolam: Pharmacology and Uses , 1985, Anesthesiology.
[26] S L Shafer,et al. Pharmacokinetics of Computer‐controlled Alfentanil Administration in Children Undergoing Cardiac Surgery , 1995, Anesthesiology.
[27] J. Dundee,et al. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. , 1988, British journal of anaesthesia.
[28] M. Hynynen. Binding of fentanyl and alfentanil to the extracorporeal circuit. , 1988, Acta anaesthesiologica Scandinavica.
[29] É. Jacqz-Aigrain,et al. Pharmacokinetics of midazolam during continuous infusion in critically ill neonates , 2004, European Journal of Clinical Pharmacology.
[30] J. Chong,et al. The addition of intrathecal sufentanil and fentanyl to bupivacaine for caesarean section. , 1998, Singapore medical journal.
[31] S. Shafer,et al. Population Pharmacokinetics of Midazolam Administered by Target Controlled Infusion for Sedation following Coronary Artery Bypass Grafting , 1998, Anesthesiology.
[32] G. Tucker,et al. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. , 2002, British journal of anaesthesia.
[33] G. Koren,et al. Preliminary Studies of the Effects of Extracorporeal Membrane Oxygenator on the Disposition of Common Pediatric Drugs , 1993, Therapeutic drug monitoring.
[34] R. Nelson,et al. Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation. , 1993, The Journal of thoracic and cardiovascular surgery.
[35] W. Hop,et al. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants , 2001, Clinical pharmacology and therapeutics.
[36] W. Trager,et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.
[37] F. Reynolds,et al. Extracorporeal circuit sequestration of fentanyl and alfentanil. , 1986, British journal of anaesthesia.
[38] H. Mulla,et al. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation , 2000, Perfusion.